medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2015, Number 2

<< Back Next >>

Arch Neurocien 2015; 20 (2)

A systematic review of combined olanzapine-fluoxetine as therapy for bipolar depression in adult and adolescent patients

Vargas-Huicochea I, Tamayo JM, Ruiz I

Language: English
References: 47
Page: 122-136
PDF size: 149.14 Kb.


ABSTRACT

Objective: this systematic review assessed the safety and efficacy of olanzapine-fluoxetine combination (OFC) for treatment of bipolar depression, specifically in studies of 8 to 12 weeks duration in adults (primary objective) and adolescents (secondary objective). Materials and methods: trials were identified using MEDLINE, EMBASE, Cochrane Library, Web of Knowledge, LILACS, WHOLIS, NEURO, Latindex, and DIALNET (2000 – July 2014). English and Spanish free-text and MeSH terms were used. Searches were supplemented with identified trials (Clinical Trials.gov) and congress abstracts. Evidence from randomized controlled trials (RCTs), nonrandomized trials, and meta-analyses were considered. Results: nine publications reporting 5 RCTs (6 publications), 1 nonrandomized trial, and 2 metaanalyses were included. One RCT was conducted in adolescents and one RCT was conducted in a Latin American population. Studies enrolled from 34 to 833 participants, were conducted for 7 to 8 weeks and up to 6 months, and varied in methodological quality and reporting. The efficacy of OFC (depression rating scales, response and remission rates) was greater compared with olanzapine monotherapy, lamotrigine monotherapy, and placebo. OFC was well tolerated in adults and adolescents. However, there was a greater frequency of weight gain, somnolence, nausea, diarrhea, and elevated metabolic parameters in participants receiving OFC versus active comparators or placebo. Conclusions: this systematic review presents findings that OFC is effective and generally well tolerated for acute treatment of bipolar depression in adults and adolescents. Existing evidence suggests that the efficacy and safety profile of OFC in patients from Latin America is not different to Caucasian populations.


REFERENCES

  1. McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord 2003;5 Suppl 2:20-35.

  2. Kasper S. Issues in the treatment of bipolar disorder. Eur Neuropsychopharmacol 2003;13 Suppl 2:S37-42.

  3. Oswald P, Souery D, Kasper S, Lecrubier Y, Montgomery S, Wyckaert S, et al. Current issues in bipolar disorder: a critical review. Eur Neuropsychopharmacol 2007;17(11):687-95.

  4. Connolly KR, Thase ME. The clinical management of bipolar disorder: a review of evidence-based guidelines. Prim Care Companion CNS Disord 2011;13(4). DOI 10.4088/ PCC.10r01097.

  5. World Health Organization. The global burden of disease 2004 update. Geneva, Switzerland: WHO Press, 2009.

  6. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011;68(3):241-51.

  7. Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions. Lancet 2013;381(9878):1663-71.

  8. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press; 2007.

  9. Post RM, Leverich GS, Kupka RW, Keck PE, Jr, McElroy SL, Altshuler LL, et al. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry 2010;71(7):864-72.

  10. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Mller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psych 2010;11(2):81-109.

  11. Nivoli AMA, Colom F, Murru A, Pacchiarotti I, Castro-Loli P, Gonzalez-Pinto A, et al. New treatment guidelines for acute bipolar depression: A systematic review. J Affect Disord 2011;129(1-3):14-26.

  12. Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR, et al. The Texas Implementation of Medication Algorithms: Update to the algorithms for treatment of bipolar I disorder. J Clinical Psych 2005; 66(7):870-86.

  13. Yatham LN, Kennedy SH, O’Donovan C, Parikh SV, MacQueen G, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006;8(6):721-39.

  14. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2013. Bipolar Disord 2013;15(1):1-44.

  15. Malhi GS, Adams D, Lampe L, Paton M, O’Connor N, Newton LA, et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand 2009;119 Suppl 439:S27-46.

  16. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: Revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacology 2009;23(4):346-88.

  17. Córdova A, Platas E, Rodríguez D, Torres L, Zamora M. Diagnóstico y tratamiento del trastorno bipolar. Evidencias y recomendaciones. Catálogo maestro de Guías de Práctica Clínica. Colonia Juarez Delegacion Cuauhtemoc, CP06600, Mexico, D.F: CENETEC; 2009.

  18. Heeren O, Sanchez De Carmona M, Vasquez G, Cordoba R, Forero J, Madrid L, et al. Psychopharmacological treatment of bipolar disorder in Latin America. Rev Psiquiatr Salud Ment 2011;4(4):205-11.

  19. Ghaemi SN, Ko JY, Goodwin FK. “Cade’s diseas and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002;47(2):125-34.

  20. Levy D, Kimhi R, Barak Y, Aviv A, Elizur A. Antidepressantassociated mania: a study of anxiety disorders patients. Psychopharmacology (Berl) 1998;136(3):243-6.

  21. McIntyre RS, Cha DS, Kim RD, Mansur RB. A review of FDAapproved treatment options in bipolar depression. CNS Spectr 2013;18 Suppl 1:4-20.

  22. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Ef ficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60(11):1079-88.

  23. Symbyax [Prescribing information]. Indianapolis: Eli Lilly and Company USA; 2014.

  24. Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C, Mitchell PB, et al. ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacology 2008;18(7):535-49.

  25. Strech D, Soltmann B, Weikert B, Bauer M, Pfennig A. Quality of reporting of randomized controlled trials of pharmacologic treatment of bipolar disorders: a systematic review. J Clin Psychiatry 2011;72(9):1214-21.

  26. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for repor ting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.

  27. A study for assessing treatment of patients ages 10-17 with bipolar depression [NCT00844857] (16 January 2013). www.Clinicaltrials.gov: US National Institutes of Health; 2013. Accessed on 9 July 2014.

  28. Brown E, Dunner DL, McElroy SL, Keck PE, Adams DH, Degenhardt E, et al. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol 2009;12(6):773-82.

  29. Tamayo JM, Sutton VK, Mattei MA, Diaz B, Jamal HH, Vieta E, et al. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol 2009;29(4):358-61.

  30. Corya SA, Perlis RH, Keck Jr PE, Lin DY, Case MG, Williamson DJ, et al. A 24-week open-label extension study of olanzapinefluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry 2006;67(5):798-806.

  31. Brown EB, McElroy SL, Keck Jr PE, Deldar A, Adams DH, Tohen M, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006;67(7):1025-33.

  32. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression—lack of manic induction. J Affect Disord 2005;87(1):121-30.

  33. Vieta E, Locklear J, Gunther O, Ekman M, Miltenburger C, Chatterton ML, et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Psychopharmacol 2010;30(5):579-90.

  34. Selle V, Schalkwijk S, Vazquez GH, Baldessarini RJ. Treatments for acute bipolar depression: Meta-analyses of placebocontrolled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014;47(2):43-52.

  35. Trivedi MH, Thase ME, Osuntokun O, Henley DB, Case M, Watson SB, et al. An integrated analysis of olanzapine/ fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psych 2009;70(3):387-96.

  36. Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psych 2007;164(10):1547-56.

  37. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders. ISBD task force report on antidepressant use in bipolar disorders. Am J Psych 2013;170(11):1249-62.

  38. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164(4):549-50.

  39. Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 2012;201(5):376-82.

  40. Milsap RL HM, Szefler SJ. Special Pharmacokinetic Considerations in Children. In: Evans WE SJ, Jusko WJ, editor. Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring. 3rd ed. Spokane, WA: Applied Therapeutics, Inc, 1992:1-25.

  41. Rodman JH. Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design. J Adolesc Health. 1994;15(8):654-62.

  42. Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry 2009;70(2):247-58.

  43. Stephenson CM, Pilowsky LS. Psychopharmacology of olanzapine. A review. Br J Psychiatry Suppl 1999(38):52-8.

  44. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother. 2002;3(10):1381-91.

  45. Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry. 2002;14(3):163-73.

  46. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64(20):2291-314.

  47. Tamayo JM, Mazzotti G, Tohen M, Gattaz WF, Zapata R, Castillo JJ, et al. Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. J Clin Psychopharmacol 2007;27(2):126-34.




2020     |     www.medigraphic.com